Why the study?
Does extended thromboprophylaxis reduce VTE in acutely ill medical patients after hospitalization?
Does extended thromboprophylaxis reduce VTE in acutely ill medical patients after hospitalization?
This review highlights the paradigm shift towards individualized, extended VTE prophylaxis in high-risk acutely ill medical patients post-discharge, supported by recent evidence and FDA approval of betrixaban.
No takes yet. Share an insight, caveat, or question.
Supports individualized extended prophylaxis in select high-risk patients; leaves open optimal selection, duration, and broader adoption.
Mahan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: